RICHMOND, Va. / May 13, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer and Jonathan Leon, the Company’s Senior Vice President-Finance and Corporate Treasurer, will be participating in a webcasted fireside chat at 5:20 p.m. Eastern Daylight Time on Wednesday, May 15, 2024 at BofA Securities’ 2024 Health Care Conference in Las Vegas, Nevada. Owens & Minor is also hosting one-on-one meetings with investors at the conference.
Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/ at least 10 minutes in advance to register for the live webcast of the discussion. A replay of the webcast can be accessed following the presentation at the link provided above.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
Last Trade: | US$6.77 |
Daily Change: | 0.12 1.80 |
Daily Volume: | 1,780,815 |
Market Cap: | US$522.030M |
February 28, 2025 February 11, 2025 February 03, 2025 December 02, 2024 November 04, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load